FDA Approved: ZEVALIN — Supplemental Application (Acrotech Biopharma Inc)

View source ↗

Summary

FDA granted approval of a supplemental application for Zevalin (ibrutinomab tiuxetan) submitted by Acrotech Biopharma, resulting in updated labeling.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Follicular Lymphoma
• Non-hodgkin Lymphoma

Drugs mentioned

• Zevalin (ibritumomab tiuxetan)

Snippet

SUPPL AP for ZEVALIN (IBRITUMOMAB TIUXETAN)